Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Genitourinary 2Breast 2

Conditions

Solid Tumor 7Ovarian Neoplasms 3Prostatic Neoplasms 2Breast Neoplasms 2Small Cell Lung Carcinoma 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × senaparib × Clear all
NCT04089189 2026-01-28

SABRINA

Impact Therapeutics, Inc.

Phase 2 Completed
93 enrolled
Gynecologic

Ovarian Neoplasms

NCT03507543 2021-03-30

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

Phase 1 Completed
39 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT03508011 2021-03-30

A Study of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

Phase 1 Completed
57 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡